|
|
|
| Study on the Expression Level of ki-67 in Non-small Cell Lung Cancer,EGFR Mutation and Clinical Correlation |
| Department of Pathology,gongyi city People's Hospital,gongyi city,Henan 451200 |
|
|
|
|
Abstract Objective To investigate the expression level of cell proliferation-associated antigen（ki-67）in non-small cell lung cancer（NSCLC）and the mutation of vascular endothelial growth factor receptor（EGFR）and its clinical correlation. Methods 56 patients with NSCLC were collected and divided into groups according to whether ki-67 was positive or not.Tissue samples were collected after surgical resection or biopsy.Immunohistochemistry and Super-ARMS were used to determine the expression of ki-67 and EGFR mutation,respectively.Spearman analyzed the correlation between ki-67 expression level and EGFR mutation and clinic. Results Except gender,age,histological type,lymph node metastasis and distant metastasis,the proportion of moderate/low differentiation and TNM stage Ⅲ+Ⅳ in ki-67 positive group was higher than that in ki-67 negative group,and the difference was statistically significant（P<0.05）.The ratio of wild type in ki-67 positive group was higher than that in ki-67 negative group,and the difference was statistically significant（P<0.05）.Spearman correlation showed that the expression level of ki-67 was negatively correlated with EGFR mutation（r=-0.382,P=0.004）,but positively correlated with differentiation degree and TNM stage（r=0.356,P=0.007;r=0.306,P=0.022）. Conclusion ki-67 expression and EGFR mutation can both participate in the occurrence and progress of NSCLC,and there is a correlation between ki-67 expression and EGFR mutation,which suggests that they can play a synergistic role.Therefore,the combination of clinical features,ki-67 expression and EGFR mutation can provide key guidance for clinical diagnosis and treatment.
|
|
Received: 04 May 2023
|
|
|
|
|
|
[1] 张语涵,张耀帅,牛雯雯,等.阿美替尼对非小细胞肺癌细胞增殖、侵袭和迁移的影响[J].中南大学学报(医学版),2021,46(10):1045-1053.
[2] Bade BC,Dela Cruz CS.Lung Cancer 2020:Epidemiology,Etiology,and Prevention[J].Clin Chest Med.2020,41(1):1-24.
[3] 司华,闫灿,曾宪焕.TN-C和Ki-67的表达与非小细胞肺癌临床病理特征的相关性[J].实用癌症杂志,2021,36(3):360-363.
[4] 武卫红,李琼洁,徐晶,等.吉非替尼治疗非小细胞肺癌患者表皮生长因子受体突变的疗效及与Ki-67表达的关系[J].西北药学杂志,2021,36(4):632-637.
[5] 中华医学会病理学分会.非小细胞肺癌分子病理检测临床实践指南[J].中华病理学杂志,2021,50(4):323-332.
[6] 张佳佳,张艳萍,刘玉辉,等.NapsinA、NSE、Ki67表达结合临床病理分析在肺癌早期诊断中的意义[J].实用癌症杂志,2019,34(9):1441-1444.
[7] 张卫东,江刚,吴怀球,等.细胞核相关抗原(Ki67)和p53表达对非小细胞肺癌患者预后的意义[J].中国现代医学杂志,2018,28(27):57-63.
[8] 刘越,姜文容,缪应新,等.老年非小细胞肺癌患者中EGFR突变、PD-L1、ki-67表达及其与临床特征的相关性[J].中华检验医学杂志,2022,45(3):234-239.
[9] 洪雅萍,黄韵坚,黄漳州,等.EGFR突变的晚期非小细胞肺癌患者接受一代TKI靶向治疗的效果及预后预测因子分析[J].中国癌症杂志,2022,32(7):624-634. |
| [1] |
Lin Yuehuan, Zhan Xuemei, Hu Xingjun, Wang Rong. Correlation Analysis of Female Genital HPV Infection,Cervical Lesions and Vaginal Microecology[J]. journal1, 2024, 44(2): 28-30. |
| [2] |
. [J]. journal1, 2024, 44(2): 68-70. |
| [3] |
Ding Yanhua, Men Shuai, Zhang Jiangxia, Zhang Xu, Zhang Shancun, Liu Lu, Lv Hongwei, Xiao Zhenghong. Clinical Efficacy of Bevacizumab Combined with Anlotinib in The Treatment of Non-small Cell Lung Cancer and Its Influence on Immune Status[J]. journal1, 2024, 44(1): 41-44. |
| [4] |
Li Guangduo. Correlation Between Serum GLP-1 Expression Level and Adverse Maternal and Infant Outcomes in Patients with Gestational Diabetes in the Middle and Late Stages[J]. journal1, 2023, 43(5): 18-20. |
| [5] |
Ma Hongwu, Wu Weixuan, Fan Haoqin, Chen Xueyan. Predictive Value of Inflammatory Prognostic Index Combined with IL-11 for Immune Related Adverse Reactions in Advanced Non-small Cell Lung Cancer[J]. journal1, 2023, 43(5): 49-51. |
| [6] |
. [J]. journal1, 2023, 43(4): 50-52. |
|
|
|
|
2024, Vol. 44 
